You are here

  • Home
  • Archive
  • Volume 11, Issue 8
  • Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy

 

Online download statistics by month:

Online download statistics by month: August 2023 to March 2026

AbstractFullPdf
Aug 2023577579180
Sep 202331031198
Oct 202316516569
Nov 202316316362
Dec 202310911074
Jan 202410710774
Feb 2024959555
Mar 2024177177135
Apr 2024999975
May 2024828562
Jun 202410110188
Jul 202415515772
Aug 2024919042
Sep 202410310461
Oct 202410110367
Nov 2024899170
Dec 202410010179
Jan 2025929256
Feb 202514014059
Mar 2025686859
Apr 2025717154
May 2025646451
Jun 2025424928
Jul 2025110
Mar 2026110
Total310331241670